To further validate the positive correlation between AR and VM formation in vitro, we treated RCC 786O AR-low-positive cell line and SW839 AR-high-positive cell line with 10 nM dihydrotestosterone (DHT) and 10 μM enzalutamide (Enz), an FDA approved antiandrogen, respectively. This evidence concerns the gene AR and renal cell carcinoma.